胆汁淤积性肝功能障碍患者体外吸附保护性与毒性胆汁酸及胆红素的前瞻性研究
前瞻性Cyto-SOVLE研究(NCT04913298)纳入20例胆汁淤积性肝功能障碍、接受连续性肾脏替代治疗、总胆红素>10 mg/dl且透析回路中应用Cytosorb®的ICU患者,在启动后10分钟、1、3、6、12小时测定CS前后胆红素及不同胆汁酸。总胆红素和结合胆红素中位相对清除率初始为-31.8%和-30.3%,6小时后降至-4.5%和-4.8%;毒性胆汁酸GCA、TCA、GCDCA、TCDCA初始相对清除率分别为-97.4%、-94.9%、-82.5%、-86.0%,6小时后降至-32.9%、-32.7%、-12.8%、-14.3%。保护性亲水性胆汁酸UDCA、GUDCA、TUDCA初始相对清除率为-77.7%、-83.0%、-91.3%,6小时后降至-7.4%、-8.5%、-12.5%。作者认为Cytosorb®可吸附胆红素及毒性、保护性胆汁酸,但吸附器快速饱和致相对清除率迅速下降,且疏水性毒性胆汁酸与亲水性保护性胆汁酸吸附量无相关差异,其临床获益或危害需未来评估。
要点
- 20例胆汁淤积性肝功能障碍ICU患者应用Cytosorb®后,总胆红素中位相对清除率初始-31.8%,6小时降至-4.5%。
- 毒性胆汁酸GCA、TCA、GCDCA、TCDCA初始相对清除率-97.4%、-94.9%、-82.5%、-86.0%,6小时降至-32.9%、-32.7%、-12.8%、-14.3%。
- 保护性亲水性胆汁酸UDCA、GUDCA、TUDCA初始相对清除率-77.7%、-83.0%、-91.3%,6小时降至-7.4%、-8.5%、-12.5%。
- 疏水性毒性胆汁酸与亲水性保护性胆汁酸在吸附量上无相关差异。
- 作者认为Cytosorb®可吸附胆红素及毒性、保护性胆汁酸,但吸附器快速饱和,临床获益或危害需未来评估。
适用人群与场景
- 20例ICU胆汁淤积性肝功能障碍患者,接受连续性肾脏替代治疗,总胆红素>10 mg/dl,且在透析回路中应用Cytosorb®。
诊断标准与关键阈值
- 纳入标准:胆汁淤积性肝功能障碍、连续性肾脏替代治疗、总胆红素浓度>10 mg/dl、Cytosorb®应用于透析回路。
研究设计与关键结果
- 前瞻性Cyto-SOVLE研究(NCT04913298)纳入20例ICU胆汁淤积性肝功能障碍患者,在Cytosorb®启动后10分钟、1、3、6、12小时测定CS前后胆红素及不同胆汁酸。
- 总胆红素和结合胆红素中位相对清除率初始分别为-31.8%和-30.3%,6小时后降至-4.5%和-4.8%。
- 毒性胆汁酸GCA、TCA、GCDCA、TCDCA初始相对清除率分别为-97.4%、-94.9%、-82.5%、-86.0%,6小时后降至-32.9%、-32.7%、-12.8%、-14.3%。
- 保护性亲水性胆汁酸UDCA、GUDCA、TUDCA初始相对清除率分别为-77.7%、-83.0%、-91.3%,6小时后降至-7.4%、-8.5%、-12.5%。
- 疏水性毒性胆汁酸与亲水性保护性胆汁酸在吸附量上无相关差异。
证据类型、等级与局限
- 证据类型:前瞻性研究(Cyto-SOVLE,NCT04913298)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为Cytosorb®可吸附胆红素及毒性、保护性胆汁酸,但吸附器快速饱和致相对清除率迅速下降,且毒性胆汁酸与保护性胆汁酸吸附量无相关差异;其临床获益或危害需未来评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The release of toxic bile acids (BAs) in the blood of critically ill patients with cholestatic liver dysfunction might lead to the damage of various organs. Their extracorporeal elimination using the cytokine adsorber Cytosorb® (CS) (adsorption of especially hydrophobic molecules < 60 kDa) might be promising, but data proving a potential adsorption are missing so far.
METHODS: The prospective Cyto-SOVLE study (NCT04913298) included 20 intensive care patients with cholestatic liver dysfunction, continuous kidney replacement therapy, total bilirubin concentration > 10 mg/dl and the application of CS into the dialysis circuit. Bilirubin and different BAs were measured pre- and post-CS at defined timepoints (10 min, 1, 3, 6, and 12 h after initiation). Relative reduction (RR, %) was calculated with: [Formula: see text].
RESULTS: The median RR for total and conjugated bilirubin after initiation was - 31.8% and - 30.3%, respectively, and decreased to - 4.5% and - 4.8% after 6 h. A high initial RR was observed for the toxic BAs GCA (- 97.4%), TCA (- 94.9%), GCDCA (- 82.5%), and TCDCA (- 86.0%), decreasing after 6 h to - 32.9%, - 32.7%, - 12.8%, and - 14.3%, respectively. The protective hydrophilic BAs showed a comparable RR after initiation (UDCA: - 77.7%, GUDCA: - 83.0%, TUDCA: - 91.3%) dropping after 6 h to - 7.4%, - 8.5%, and - 12.5%, respectively.
CONCLUSIONS: Cytosorb® can adsorb bilirubin and toxic as well as protective BAs. However, a fast saturation of the adsorber resulting in a rapid decrease of the RR was observed. Furthermore, no relevant difference between hydrophobic toxic and hydrophilic protective BAs was detected regarding the adsorption amount. The clinical benefit or harm of the BA adsorption needs to be evaluated in the future.
参考来源
- Greimel A, Habler K, Gräfe C, et al. Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study. Ann Intensive Care. 2023. PMID: 37943350. doi:10.1186/s13613-023-01198-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。